A model for predicting response to PD-1 inhibitors in NSCLC
|Study ID||Alternative Stable ID||Type|
Whole exome sequencing was used to examine the impact of human leukocyte antigen B44 in a non-small cell lung cancer cohort treated with single agent pembrolizumab with over five years of follow-up.
|Archive||Link Archive Accession|
Who archives the data?
There are no publications available